EAU 2025 Bladder Cancer

Viewing 1-20 of 45 articles

EAU 2025: First-in-Human Study of RAG-01, a Novel Small Activating RNA Therapeutic in BCG Failure NMIBC Patients

EAU 2025: Updated Clinical & Translational Results: BOND-003 Cohort C: A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive NMIBC with CIS

EAU 2025: Cost-Effectiveness Analysis of Treatments for BCG-Unresponsive High-Risk NMIBC

EAU 2025: Translational Correlates Using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Analysis from the BOND-003 and CORE-001 Trials

EAU 2025: State-of-the-Art Lecture: TAR, a Novel Intravesical Drug Delivery System

EAU 2025: Combination Therapy: Systemic Versus Intravesical - the Dynamic Duo: Gemcitabine and Docetaxel - The Bladder Is Their Domain!

EAU 2025: Combination Therapy: Systemic Versus Intravesical - It Takes Two to Tango: Systemic and Intravesical Therapy - the Ideal Duo for Treatment of HR-NMIBC

EAU 2025: State-of-the-Art Lecture: Definitions, Outcomes and Treatment of BCG Unresponsive NMIBC

EAU 2025: Intravesical Drug Delivery: Devices Versus Vectors - What Is the Necessity for Device-Assisted Drug Delivery When We Have Viruses and Vaccines?

EAU 2025: PROGRxN-BCa, an Artificial Intelligence-Based Model to Predict Progression Risk in Non-Muscle Invasive Bladder Cancer and Improve Substratification of Intermediate-Risk Disease: An International Evaluation of 12659 Patients

EAU 2025: State-of-the-Art Lecture: The Need to De-Escalate Follow-up in the Growing Population of NMIBC Patients: Urine Diagnostics

EAU 2025: The DaBlaCa-15 Trial: The Urinary Biomarker Test Xpert® Bladder Cancer Monitor for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from a Randomized Controlled Trial

EAU 2025: Diagnostic Accuracy and Efficacy of Photodynamic Diagnosis 4-8 Hours After 5-Aminolevulinic Acid Hydrochloride Administration for Non-Muscle Invasive Bladder Cancer: An Exploratory Analysis of the Phase III SPP2C102 Trial

EAU 2025: Gene Expression Signatures of Immune Infiltration Portend Differential Response to Sequential Intravesical Gemcitabine and Docetaxel versus Bacillus Calmette-Guerin in High-Risk Non-Muscle-Invasive Bladder Cancer

EAU 2025: The Impact of PDD on Recurrence and Progression in BCG-Treated NMIBC Patients: A Nationwide Follow-up Study

EAU 2025: Artificial Intelligence System for Detecting Flat Bladder Tumors in Cystoscopic Images

EAU 2025: Bladder EpiCheck-Triggered Photodynamic Diagnosis Biopsies Detect High Grade Recurrences Missed by White Light Cystoscopy

EAU 2025: A Real-World Evidence Study Evaluating the Prevalence of FGFR Alterations in Patients with Intermediate Risk NMIBC, as Defined by the IBCG

EAU 2025: Combination Therapy: Systemic Versus Intravesical - BCG Unleashed: Harnessing Local Immunomodulators for Maximum Impact

EAU 2025: Trial in Progress: BOND-003 Cohort P- a Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

1
2
3